The Phase 3 Registration STAR Study of Efdamrofusp Alfa (IBI302) Met its Primary…
73% of participants achieved Q16W dosing interval; Furthermore, nearly 60% of the participants held the potential…
PR Newswire is a distributor of press releases headquartered in New York City.